Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.64 |
| ▸ | CA4 | P22748 | 2/20 | 0.64 |
| ▸ | CA6 | P23280 | 2/20 | 0.64 |
| ▸ | CA5A | P35218 | 2/20 | 0.64 |
| ▸ | CA7 | P43166 | 2/20 | 0.64 |
| ▸ | CA9 | Q16790 | 2/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.64 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.64 |
| ▸ | TTR | P02766 | 4/20 | 0.60 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2605865 | 0.88 | TTR (0.71) | CA12CA4CA6CA5ACA7 | |
| SCHEMBL2605864 | 0.86 | ALOX5 (0.63) | TTRAKR1B10AKR1B1LMNAAKR1C3 | |
| SCHEMBL8738318 | 0.84 | TTR (0.47) | CA12CA4CA6CA5ACA7 | |
| SCHEMBL15384085 | 0.83 | CA12 (0.81) | CA12CA4CA6CA5ACA7 | |
| SCHEMBL15384917 | 0.81 | CA12 (0.64) | CA12CA4CA6CA5ACA7 | |
| SCHEMBL15384910 | 0.81 | CA12 (0.67) | CA12CA4CA6CA5ACA7 | |
| SCHEMBL2602743 | 0.80 | CA12 (0.65) | CA12CA4CA6CA5ACA7 | |
| SCHEMBL9550145 | 0.80 | CA12 (0.76) | CA12CA4CA6CA5ACA7 | |
| SCHEMBL15384918 | 0.79 | CA12 (0.61) | CA12CA4CA6CA5ACA7 | |
| SCHEMBL16601909 | 0.79 | CA12 (0.65) | CA12CA4CA6CA5ACA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129931-A1 | CAFFEIC ACID DERIVATIVES AND THEIR USE IN IMPROVING NEURONAL CELL VIABILITY | Chemigen (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2012068038-A2 | CAFFEIC ACID DERIVATIVES AND THEIR USE IN IMPROVING NEURONAL CELL VIABILITY | Chemigen (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120100122-A1 | COMBINATION THERAPY | Chemigen (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2012054446-A2 | COMBINATION THERAPY | Chemigen (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129931-A1 | CAFFEIC ACID DERIVATIVES AND THEIR USE IN IMPROVING NEURONAL CELL VIABILITY | CCAR2, BDNF, CASP3 | CA12 682/4885CA4 453/4885CA6 408/4885 |
| US-20120100122-A1 | COMBINATION THERAPY | SLC25A20, TFAM, NDUFAB1 | CA12 3597/4885CA4 2497/4885CA6 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.